The addition of neoadjuvant pertuzumab for the treatment of HER2+ breast cancer: a cost estimate with real-world data

Health Economics Review

Luís Antunes¹  Maria José Bento¹  Francisco Rocha-Gonçalves²  Susana Sousa³  Deolinda Sousa Pereira³  Cláudia Vieira³  Filipa Pereira³  Andreia Borges⁴  Patrícia Redondo⁴  José Machado Lopes⁴  Marina Borges⁴  Pedro Antunes⁵  Joaquim Abreu de Sousa⁵ 

[1] Department of Epidemiology, Portuguese Oncology Institute of Porto (IPO Porto);Luz Saúde;Medical Oncology Department, Portuguese Oncology Institute of Porto (IPO Porto);Outcomes Research Lab, Portuguese Oncology Institute of Porto (IPO Porto);Surgical Oncology Department, Portuguese Oncology Institute of Porto (IPO Porto);

关键词: Pertuzumab;    Neoadjuvant treatment;    HER2-positive breast cancer;    Cost-effectiveness analysis;   

DOI  :  10.1186/s13561-021-00332-0

来源: DOAJ

【 摘 要 】

Highlights i. The results obtained in the AC-DHP cohort, which included Pertuzumab as a NeoT, suggest better clinical outcomes compared to the AC-DH group, a confirmation based on real-world data. ii. Some patient profiles seem to be more promising concerning the overall costs for pathological complete response, but the present data does not include a long-term follow-up period, which suggests that interpretations should be performed with caution. iii. Pertuzumab cost estimated represented a great proportion of overall total costs per patient, but further research (including the costs of the whole episode of care) and continuously monitoring (additional RWE) is needed for a more robust cost-effectiveness analysis.

【 授权许可】

Unknown